Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

1.8K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

6.2K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

599
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
599
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Grade Progression and High-Grade Transformation in Neuroendocrine Neoplasms.

Endocrine-related cancer·2026
Same author

A Toddler With Iron Deficiency Anemia Secondary to a Yolk Sac Tumor of the Stomach: A Case Report and Literature Review.

Case reports in pediatrics·2026
Same author

High interobserver variability exists in grading appendiceal goblet cell adenocarcinoma using World Health Organization 5th edition criteria.

Histopathology·2026
Same author

Digital Ki-67 quantification in neuroendocrine tumours: comparing performance of camera-captured images and open-source platforms across imaging modalities.

Journal of clinical pathology·2026
Same author

Molecular Profiling of Digestive Grade 3 Neuroendocrine Tumors Reveals a Shared Molecular Framework with Lower-Grade Tumors, Marked Heterogeneity, and Therapeutic Opportunities.

Endocrine pathology·2026
Same author

Defining hotspot for estimation of Ki-67 proliferation index of neuroendocrine tumors: QuPath algorithm vs. manual assessment.

Journal of pathology informatics·2026

Related Experiment Video

Updated: Feb 10, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.8K

Primary Biliary Cholangitis and Autoimmune Hepatitis.

Raul S Gonzalez1, Kay Washington2

  • 1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.

Surgical Pathology Clinics
|May 13, 2018
PubMed
Summary

Primary biliary cholangitis and autoimmune hepatitis are distinct autoimmune liver diseases. Diagnosis requires careful review of clinical, serologic, and histologic findings, as they can overlap or co-occur.

Keywords:
AutoantibodiesAutoimmune hepatitisBiliary diseaseChronic hepatitisDifferential diagnosisOverlap syndromePrimary biliary cholangitisPrimary biliary cirrhosis

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K

Related Experiment Videos

Last Updated: Feb 10, 2026

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
07:44

Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction

Published on: March 25, 2022

6.8K
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.9K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.4K

Area of Science:

  • Hepatology
  • Autoimmune Diseases
  • Immunology

Background:

  • Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) are prevalent autoimmune liver conditions.
  • Both diseases share overlapping clinical and serologic features, complicating diagnosis.
  • Distinct histological findings aid in differentiating PBC (bile duct destruction) and AIH (lymphoplasmacytic inflammation).

Purpose of the Study:

  • To delineate the diagnostic criteria for primary biliary cholangitis and autoimmune hepatitis.
  • To highlight the differential diagnosis between PBC and AIH.
  • To discuss the potential for simultaneous occurrence of both conditions in a single patient.

Main Methods:

  • Review of clinical presentations and serologic autoantibody profiles.
  • Analysis of characteristic histological features in liver biopsies.
  • Comparison of diagnostic criteria for PBC and AIH.

Main Results:

  • PBC typically presents with bile duct destruction, sometimes with granulomas.
  • AIH is characterized by prominent portal and lobular lymphoplasmacytic inflammation.
  • Differential diagnosis is crucial as PBC and AIH can mimic each other or coexist.

Conclusions:

  • Accurate diagnosis of PBC and AIH relies on integrating clinical, serologic, and histological data.
  • Immunosuppression is the first-line treatment for AIH, while ursodeoxycholic acid is used for PBC.
  • Both autoimmune liver diseases carry the risk of progressing to cirrhosis if not managed effectively.